Literature DB >> 6246836

The acute sensory neuronopathy syndrome: a distinct clinical entity.

A B Sterman, H H Schaumburg, A K Asbury.   

Abstract

Four to twelve days following initial antibiotic treatment for a febrile illness, three adults suddenly experienced numbness and pain over the face and entire body. Each had received a penicillin or a semisynthetic derivative, and two patients also received other antibiotics. Signs appeared rapidly and included profound sensory ataxia, areflexia, and widespread sensory loss, primarily of large fiber modalities (proprioceptive sensibility). Slowed or absent sensory conduction was found. There was no weakness, and electrical study of muscle and motor nerve conduction was normal in all. The cerebrospinal fluid was acellular, and protein levels were elevated to 126 and 175 mg/dl in two cases and were normal in the other. Presently, all have a severe, static, residual sensory deficit. During follow-up of five years, no evidence of neoplastic disease or immunological disorder has appeared. Because of the rapid onset, widespread and pure sensory involvement, and poor recovery, the lesion is most likely confined to the dorsal root and gasserian ganglia (sensory neuronopathy). This pattern resembles that of the experimental lesions induced by doxorubicin and pyridoxine. It appears likely that either the previously administered antibiotics or the illness for which they were administered were of pathogenetic importance. We designate this previously unrecognized disorder the acute sensory neuronopathy syndrome and suggest that it represents a distinct, readily identifiable clinical entity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246836     DOI: 10.1002/ana.410070413

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

1.  Functional role of unmyelinated tactile afferents in human hairy skin: sympathetic response and perceptual localization.

Authors:  Håkan Olausson; Jonathan Cole; Karin Rylander; Francis McGlone; Yves Lamarre; B Gunnar Wallin; Heidrun Krämer; Johan Wessberg; Mikael Elam; M Catherine Bushnell; Ake Vallbo
Journal:  Exp Brain Res       Date:  2007-10-26       Impact factor: 1.972

2.  Rehabilitation after sensory neuronopathy syndrome.

Authors:  J Cole
Journal:  J R Soc Med       Date:  1998-01       Impact factor: 5.344

3.  Acute ataxic neuropathy with hyperreflexia.

Authors:  Leonard L L Yeo; Kay Ng; Nobuhiro Yuki
Journal:  J Neurol       Date:  2012-11-20       Impact factor: 4.849

Review 4.  Immunology of Guillain-Barré syndrome.

Authors:  I Steiner; O Abramsky
Journal:  Springer Semin Immunopathol       Date:  1985

Review 5.  Sensory Neuronopathies.

Authors:  Allison Crowell; Kelly G Gwathmey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-23       Impact factor: 5.081

6.  Clinico-pathophysiological features of acute autonomic and sensory neuropathy: a long-term follow-up study.

Authors:  T Yasuda; G Sobue; K Mokuno; S Hakusui; T Ito; Y Hirose; T Yanagi
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

7.  Chronic idiopathic ataxic neuropathy: neuropathology of a case.

Authors:  L T Simon; G A Ricaurte; L S Forno
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Body sway and vibration perception thresholds in normal aging and in patients with polyneuropathy.

Authors:  P S Bergin; A M Bronstein; N M Murray; S Sancovic; D K Zeppenfeld
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

9.  Polyneuropathy in critically ill patients.

Authors:  C F Bolton; J J Gilbert; A F Hahn; W J Sibbald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

10.  Cortical responses to Aδ-fiber stimulation: magnetoencephalographic recordings in a subject lacking large myelinated afferents.

Authors:  Gina Caetano; Håkan Olausson; Jonathan Cole; Veikko Jousmäki; Riitta Hari
Journal:  Cereb Cortex       Date:  2009-12-03       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.